Ray B. Nagle, MD, PhD

Professor Emeritus, Pathology, Cell Biology and Anatomy, and Surgery

 

E-Mail Address: 
Phone Number: 
(520) 626-5566
Short Bio: 

Dr. Nagle is a Professor Emeritus of Pathology, Cell Biology and Anatomy, and Surgery at The University of Arizona, and former medical director at Ventana Medical Systems in Tucson, Arizona. He previously served as Deputy Director (1997-2003) and Interim Director (2003-2005) of The University of Arizona Cancer Center.

From 2001-2014 he served as the Director of the Tissue Acquisition and Cellular/Molecular Analysis Shared Resource (TACMASR), which is part of the University of Arizona Cancer Center Core Grant.

His major research interests involve molecular pathology studies in prostate carcinogenesis. His research program has focused for the past several years on understanding the biological basis for the variability in the clinical evolution and spread of prostate cancer. In collaboration with Drs. Anne Cress, Timothy Bowden, Ronald Heimark and many others, his group has worked to define molecular events during the progression of the disease that allow the cancer to migrate out of the site of origin in the prostate and thus metastasize to the bone and other sites. Such knowledge may provide the basis for predicting the probable outcome of an individual’s tumor as well as suggest approaches to block the evolution and dissemination of prostate cancer.

His current research interests continue to explore factors involved in early prostate cancer invasion. His research has previously described that through a process of collective invasion, genetically unstable cells found in PIN lesions invade the prostate stroma. In this process the invasive cells maintain cohesion and are surrounded by an altered basal lamina containing laminins 10 and 11, but deficient in laminin 5. Recent work has described translational control of the three chains of laminin 5 as well as its receptor integrin β4 by miRNA 205 which in turn is regulated by miRNA 184.  They are currently investigating the role of these molecules in prostate cancer invasion using clinical material as well as cell lines.

Dr. Nagle received combined training in anatomic and clinical pathology at the University of Washington. Subsequently, he received an NIH post-doctoral fellowship in experimental pathology which led to a Ph.D. degree. He was an associate pathologist in the Department of Experimental Pathology at Walter Reed Army Institute of Research where he was involved in studies of pathogenesis of African Trypanosomiasis as well as acute renal failure. Following military service, he served on the faculty at the University of Maryland where his research primarily dealt with mechanisms of acute renal failure as well as models of experimental glomerulonephritis. In 1968 he joined the faculty at the University of Arizona College of Medicine. His work as a surgical pathologist led to a research program focusing on the role and identification of cytokeratins in the diagnosis of human neoplasms.

Dr. Nagle has administered over 28 funded research grants, and authored over 250 peer-reviewed papers and abstracts in the area of solid tumor pathology and prostate cancer progression.

Clinical Information
Specialty: 
Pathologist
Research Information
Research Program: 
3. Cancer Biology
Member Status: 
Affiliate Member
Selected Publications: 

Pawar SC, Demetriou MC, Nagle RB, Bowden GT, Cress AE. Integrin α6 cleavage: A novel modification to modulate cell migration. Exp Cell Res 313(6):1080-89, 2007.

Sroka IC, Pond GD, Nagle RB, Porreca F, King T, Pestano G, Futscher BW, Gard JM, Riley J, Sathyanarayana UG, Cress AE: Human cell surface receptors as molecular imaging candidates for metastatic cancer. The Open Prostate Cancer Journal Vol 2, pp59-66 (8), 2009. 

Sroka IC, Anderson TA, McDaniel KM, Nagle RB, Gretzer MB, Cress AE: The Q1 laminin binding integrin a6b1 in prostate cancer perineural invasion. Mini-Review JCP10-0081(22149), J Cell Physiol 9999: 1-6, 2010. Review.PMID:20432448 

Nagle RB; Cress AE;. Metastasis Update: Human Prostate Carcinoma Invasion via Tubulogenesis. Review article published online in UroToday. Prostate Cancer Article ID 249290, doi:10.1155/2011/249290/pubmed 21049592.  2011

Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Chiu HH, Dalkin BL, Sindwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP:  Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer.  First published 10 AUG 2012 DOI:10:1002/pros.22673.  PROS 12-162-R1 (122573)  The Prostate 73:328-335 (2013). 

Nagle RB,Algotar A, Cortez CC, Smith K, Jones C, SathyanarayanaUG, Uyn S, Riley J, Nagy D, Dittamore R, Dalkin B, Brosh L, Pestano G:  ERG Overexpression and PTEN status predict capsular penetration in prostate carcinoma.  The Prostate #PROS-13-071.R1, March 25, 2013.  

Hassounah NB, Nagle R, Saboda K, Roe DJ, Dalkin BL ,McDermott KM. (2013) Primary Cilia Are Lost in Preinvasive and Invasive Prostate Cancer. PLoS ONE 8(7): e68521. doi:10.1371/journal.pone.0068521, May 2013

Sathyanarayana UG, Birch C, Nagle RB, Tomlins SA, Palanisamy N, Zhang W, Hubbard A, Bruenhober P, Wang Y, Tang L.  Determination of optimum formalin fixation duration for prostate needle biopsies for Immunohistochemistry and Quantum dot FISH analysis. Applied Immunohistochem & Molecular Morphology, AIMM-141388R1, Accepted Feb 2014 doi: 10.1097/PAI.0000000000000085, PMID 25265431

Landowski TH, Gard J, Pond E, Pond GD, Nagle RB, Geffre CP, Cress AE. Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model. Mol Cancer Ther. 2014 Jun;13(6):1558-66. doi: 10.1158/1535-7163.MCT-13-0962. Epub 2014 Apr 16. PMID:24739392

Kacsinta A, Rubenstein CK, Sroka IC, Pawar S; Gard J,  Nagle RB, Cress AE. Intracellular Modifiers of Integrin Alpha 6p Production in Aggressive Prostate and Breast Cancer Cell Lines. Biochemical and Biophysical Research Communications, Vol. 454, Issue 2, Nov 14, 2014, pages 335-340. doi:10.1016/j.bbrc.2014.10.073. PMCID: PMC4254650 (Available on 2015/11/14).

Geffre CP, Pond E, Pond GD, Sroka IC, Gard JM, Skovan BA, Meek WE, Landowski TH, Nagle RB, Cress AE. Combined micro CT and histopathology for evaluation of skeletal metastasis in live animals. Journal Translational Research 2014, accepted.

Professional Information
Board Certifications: 

College of American Pathologists

Honors: 

Recipient of the 2004 Founder's Day Award

Recipient of the 2009 “Distinguished Senior Investigator” Salmon Award at the Arizona Cancer Center

Academic Information
Fellowship: 
Experimental Pathology
Residency: 
University of Washington, Seattle, WA
Doctorate: 
University of Washington, Seattle, WA
Medical School: 
University of Washington, Seattle, WA
Undergraduate School: 
Washington State University, Pullman, WA